EXPLORE THE SCIENCE
TL;DR: A 2026 study in Translational Psychiatry found that ketamine changed EEG-derived high-order brain interactions in late-life treatment-resistant depression, and a 24-hour increase in alpha-band redundancy tracked greater depression improvement by Day 7.…
Read article
TL;DR: A 2026 narrative review in Molecular Psychiatry argues that depression in Alzheimer’s disease and Parkinson’s disease follows disease-specific brain mechanisms, while standard antidepressant evidence remains weak in these neurodegenerative populations.…
Read article
TL;DR: A 2026 systematic review and meta-analysis in Molecular Psychiatry found that CB-1 receptor blockade and cannabidiol reduced alcohol intake in animal models, but human alcohol-use-disorder evidence remained inconsistent and too thin to support a treatme…
Read article
TL;DR: A 2026 study in International Clinical Psychopharmacology described a 40-year-old man whose dysphoria, anhedonia, amotivation, and fatigue appeared soon after olanzapine was changed to olanzapine-samidorphan and resolved after he returned to olanzapine…
Read article
TL;DR: A 2026 medRxiv retrospective cohort study found that depression often followed bipolar manic or mixed episodes quickly, with 25% of manic episodes and 22% of mixed episodes transitioning to depression within 1 month. Key Findings First-month risk window…
Read article
TL;DR: A 2026 study in The British Journal of Psychiatry found that 4 weeks of twice-weekly subcutaneous racemic ketamine helped a minority of people with treatment-resistant depression, but response fell from 30% at treatment end to 17% 4 weeks later. Key Fin…
Read article
TL;DR: A 2026 systematic review and meta-analysis in Pain Medicine found that Medicaid enrollment and preoperative benzodiazepine use had the largest pooled associations with new persistent opioid use after surgery among opioid-naive US adults. Key Findings 27…
Read article
TL;DR: A 2026 study in Neuropsychopharmacology found that 30 mg 2C-B produced acute subjective effects in healthy adults that were similar in overall intensity to 125 mg MDMA, shorter and less distressing than 25 mg psilocybin, and less cardiovascularly stimul…
Read article
TL;DR: A 2026 retrospective analysis posted to medRxiv linked diclofenac and naproxen use in the NACC cohort to lower dementia and Alzheimer disease prevalence, while diclofenac use was also associated with slower Montreal Cognitive Assessment (MoCA) cognitive…
Read article
TL;DR: A 2026 protocol posted to medRxiv describes a nationwide Japan survey designed to measure how dementia specialists handle anti-amyloid antibody therapy, biomarker testing, MRI safety monitoring, service capacity, and patient-choice tradeoffs. Key Findin…
Read article